190 related articles for article (PubMed ID: 15690056)
1. Decorin prevents metastatic spreading of breast cancer.
Reed CC; Waterhouse A; Kirby S; Kay P; Owens RT; McQuillan DJ; Iozzo RV
Oncogene; 2005 Feb; 24(6):1104-10. PubMed ID: 15690056
[TBL] [Abstract][Full Text] [Related]
2. Decorin suppresses bone metastasis in a breast cancer cell line.
Araki K; Wakabayashi H; Shintani K; Morikawa J; Matsumine A; Kusuzaki K; Sudo A; Uchida A
Oncology; 2009; 77(2):92-9. PubMed ID: 19590249
[TBL] [Abstract][Full Text] [Related]
3. Decorin suppresses lung metastases of murine osteosarcoma.
Shintani K; Matsumine A; Kusuzaki K; Morikawa J; Matsubara T; Wakabayashi T; Araki K; Satonaka H; Wakabayashi H; Iino T; Uchida A
Oncol Rep; 2008 Jun; 19(6):1533-9. PubMed ID: 18497961
[TBL] [Abstract][Full Text] [Related]
4. Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development.
Ursini-Siegel J; Rajput AB; Lu H; Sanguin-Gendreau V; Zuo D; Papavasiliou V; Lavoie C; Turpin J; Cianflone K; Huntsman DG; Muller WJ
Mol Cell Biol; 2007 Sep; 27(18):6361-71. PubMed ID: 17636013
[TBL] [Abstract][Full Text] [Related]
5. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
Klos KS; Wyszomierski SL; Sun M; Tan M; Zhou X; Li P; Yang W; Yin G; Hittelman WN; Yu D
Cancer Res; 2006 Feb; 66(4):2028-37. PubMed ID: 16489002
[TBL] [Abstract][Full Text] [Related]
6. Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin.
Reed CC; Gauldie J; Iozzo RV
Oncogene; 2002 May; 21(23):3688-95. PubMed ID: 12032837
[TBL] [Abstract][Full Text] [Related]
7. A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling.
Yoon SO; Shin S; Lipscomb EA
Cancer Res; 2006 Mar; 66(5):2732-9. PubMed ID: 16510594
[TBL] [Abstract][Full Text] [Related]
8. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
Buijs JT; Henriquez NV; van Overveld PG; van der Horst G; Que I; Schwaninger R; Rentsch C; Ten Dijke P; Cleton-Jansen AM; Driouch K; Lidereau R; Bachelier R; Vukicevic S; Clézardin P; Papapoulos SE; Cecchini MG; Löwik CW; van der Pluijm G
Cancer Res; 2007 Sep; 67(18):8742-51. PubMed ID: 17875715
[TBL] [Abstract][Full Text] [Related]
9. ErbB3-dependent motility and intravasation in breast cancer metastasis.
Xue C; Liang F; Mahmood R; Vuolo M; Wyckoff J; Qian H; Tsai KL; Kim M; Locker J; Zhang ZY; Segall JE
Cancer Res; 2006 Feb; 66(3):1418-26. PubMed ID: 16452197
[TBL] [Abstract][Full Text] [Related]
10. Decorin transfection induces proteomic and phenotypic modulation in breast cancer cells 8701-BC.
Pucci-Minafra I; Cancemi P; Di Cara G; Minafra L; Feo S; Forlino A; Tira ME; Tenni R; Martini D; Ruggeri A; Minafra S
Connect Tissue Res; 2008; 49(1):30-41. PubMed ID: 18293176
[TBL] [Abstract][Full Text] [Related]
11. In vitro growth inhibition of ovarian cancer cells by decorin: synergism of action between decorin and carboplatin.
Nash MA; Loercher AE; Freedman RS
Cancer Res; 1999 Dec; 59(24):6192-6. PubMed ID: 10626812
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer.
Hiraga T; Myoui A; Choi ME; Yoshikawa H; Yoneda T
Cancer Res; 2006 Feb; 66(4):2067-73. PubMed ID: 16489006
[TBL] [Abstract][Full Text] [Related]
13. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.
Moore LD; Isayeva T; Siegal GP; Ponnazhagan S
Clin Cancer Res; 2008 Aug; 14(15):4961-70. PubMed ID: 18676771
[TBL] [Abstract][Full Text] [Related]
14. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors.
Tan M; Li P; Sun M; Yin G; Yu D
Oncogene; 2006 Jun; 25(23):3286-95. PubMed ID: 16407820
[TBL] [Abstract][Full Text] [Related]
15. An anti-oncogenic role for decorin. Down-regulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells.
Santra M; Eichstetter I; Iozzo RV
J Biol Chem; 2000 Nov; 275(45):35153-61. PubMed ID: 10942781
[TBL] [Abstract][Full Text] [Related]
16. Decorin-induced growth inhibition is overcome through protracted expression and activation of epidermal growth factor receptors in osteosarcoma cells.
Zafiropoulos A; Nikitovic D; Katonis P; Tsatsakis A; Karamanos NK; Tzanakakis GN
Mol Cancer Res; 2008 May; 6(5):785-94. PubMed ID: 18505923
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor-beta1 regulation of ATF-3 and identification of ATF-3 target genes in breast cancer cells.
Kwok S; Rittling SR; Partridge NC; Benson CS; Thiyagaraj M; Srinivasan N; Selvamurugan N
J Cell Biochem; 2009 Oct; 108(2):408-14. PubMed ID: 19582787
[TBL] [Abstract][Full Text] [Related]
18. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.
Kunz C; Borghouts C; Buerger C; Groner B
Mol Cancer Res; 2006 Dec; 4(12):983-98. PubMed ID: 17189388
[TBL] [Abstract][Full Text] [Related]
19. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
Zhang H; Stephens LC; Kumar R
Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
[TBL] [Abstract][Full Text] [Related]
20. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells.
Kim KK; Lee JJ; Yang Y; You KH; Lee JH
Carcinogenesis; 2008 Apr; 29(4):704-12. PubMed ID: 18258606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
